IN2014DN10670A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10670A
IN2014DN10670A IN10670DEN2014A IN2014DN10670A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A IN 10670DEN2014 A IN10670DEN2014 A IN 10670DEN2014A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A
Authority
IN
India
Prior art keywords
compound
treating
formula
methods
pharmaceutically acceptable
Prior art date
Application number
Inventor
I Robert Silverman
Julie F Liu
Adam J Morgan
Bhaumik Pandya
Scott L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2014DN10670A publication Critical patent/IN2014DN10670A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
IN10670DEN2014 2012-06-15 2013-06-14 IN2014DN10670A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02
PCT/US2013/045919 WO2013188783A1 (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib

Publications (1)

Publication Number Publication Date
IN2014DN10670A true IN2014DN10670A (en) 2015-08-28

Family

ID=48699982

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10670DEN2014 IN2014DN10670A (en) 2012-06-15 2013-06-14

Country Status (11)

Country Link
EP (3) EP3450434B1 (en)
AU (3) AU2013274030B2 (en)
BR (2) BR112014031204A2 (en)
CA (1) CA2876306C (en)
DK (1) DK3450434T3 (en)
EA (1) EA201492287A1 (en)
ES (1) ES2867048T3 (en)
IN (1) IN2014DN10670A (en)
MX (1) MX360495B (en)
PL (1) PL3450434T3 (en)
WO (1) WO2013188783A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612196T3 (en) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
KR102354472B1 (en) 2010-03-10 2022-01-21 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP5876146B2 (en) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
IN2014DN10670A (en) 2012-06-15 2015-08-28 Concert Pharmaceuticals Inc
HUE055894T2 (en) 2012-11-15 2021-12-28 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
EP3148545B1 (en) 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
US11033490B2 (en) * 2016-12-14 2021-06-15 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
KR20210124345A (en) * 2019-02-06 2021-10-14 콘서트 파마슈티컬즈, 인크. Methods of Preparing Enantiomerically Rich JAK Inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3228505A1 (en) 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN117384163A (en) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 Compound containing gem difluoro group and preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
ES2612196T3 (en) * 2005-12-13 2017-05-12 Incyte Holdings Corporation Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
WO2009094216A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JOP20190230A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
IN2014DN10670A (en) 2012-06-15 2015-08-28 Concert Pharmaceuticals Inc
HUE055894T2 (en) * 2012-11-15 2021-12-28 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib

Also Published As

Publication number Publication date
MX360495B (en) 2018-11-06
EP3450434B1 (en) 2021-02-24
CA2876306C (en) 2024-02-20
EP3882249A1 (en) 2021-09-22
AU2013274030B2 (en) 2016-07-07
DK3450434T3 (en) 2021-05-03
EA201492287A1 (en) 2015-07-30
BR112014031204A2 (en) 2017-06-27
WO2013188783A8 (en) 2014-02-27
AU2018271227A1 (en) 2018-12-13
AU2016238877B2 (en) 2018-08-30
AU2018271227B2 (en) 2020-08-27
EP3450434A1 (en) 2019-03-06
MX2014015185A (en) 2015-02-17
CA2876306A1 (en) 2013-12-19
BR122023027277A2 (en) 2024-01-23
EP2861600A1 (en) 2015-04-22
AU2013274030A1 (en) 2015-01-22
PL3450434T3 (en) 2021-10-04
AU2016238877A1 (en) 2016-10-27
ES2867048T3 (en) 2021-10-20
WO2013188783A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
IN2014DN10670A (en)
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
IN2015DN01156A (en)
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IN2014MN02598A (en)
MX361499B (en) Deuterated baricitinib.
JO3148B1 (en) Notch pathway signaling inhibitor compound
GB201106750D0 (en) Novel compounds
IN2015DN00598A (en)
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
SG11201406311UA (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IN2014DN06869A (en)
MX362879B (en) Novel uses.
MX2016004934A (en) Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
IN2014DN07996A (en)
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA201270728A1 (en) PURINE CONNECTIONS
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
IN2014DN03010A (en)
PH12016500809B1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
UA110834C2 (en) Compound inhibitor of notch signaling pathway